TY - JOUR
T1 - Frailty, mortality, and health care utilization after liver transplantation
T2 - From the Multicenter Functional Assessment in Liver Transplantation (FrAILT) Study
AU - from the Multi-Center Functional Assessment in Liver Transplantation (FrAILT) Study
AU - Lai, Jennifer C.
AU - Shui, Amy M.
AU - Duarte-Rojo, Andres
AU - Ganger, Daniel R.
AU - Rahimi, Robert S.
AU - Huang, Chiung Yu
AU - Yao, Frederick
AU - Kappus, Matthew
AU - Boyarsky, Brian
AU - McAdams-Demarco, Mara
AU - Volk, Michael L.
AU - Dunn, Michael A.
AU - Ladner, Daniela P.
AU - Segev, Dorry L.
AU - Verna, Elizabeth C.
AU - Feng, Sandy
N1 - Publisher Copyright:
© 2021 American Association for the Study of Liver Diseases.
PY - 2022/6
Y1 - 2022/6
N2 - Background and Aims: Frailty is a well-established risk factor for poor outcomes in patients with cirrhosis awaiting liver transplantation (LT), but whether it predicts outcomes among those who have undergone LT is unknown. Approach and Results: Adult LT recipients from 8 US centers (2012–2019) were included. Pre-LT frailty was assessed in the ambulatory setting using the Liver Frailty Index (LFI). “Frail” was defined by an optimal cut point of LFI ≥ 4.5. We used the 75th percentile to define “prolonged” post-LT length of stay (LOS; ≥12 days), intensive care unit (ICU) days (≥4 days), and inpatient days within 90 post-LT days (≥17 days). Of 1166 LT recipients, 21% were frail pre-LT. Cumulative incidence of death at 1 and 5 years was 6% and 16% for frail and 4% and 10% for nonfrail patients (overall log-rank p = 0.02). Pre-LT frailty was associated with an unadjusted 62% increased risk of post-LT mortality (95% CI, 1.08–2.44); after adjustment for body mass index, HCC, donor age, and donation after cardiac death status, the HR was 2.13 (95% CI, 1.39–3.26). Patients who were frail versus nonfrail experienced a higher adjusted odds of prolonged LT LOS (OR, 2.00; 95% CI, 1.47–2.73), ICU stay (OR, 1.56; 95% CI, 1.12–2.14), inpatient days within 90 post-LT days (OR, 1.72; 95% CI, 1.25–2.37), and nonhome discharge (OR, 2.50; 95% CI, 1.58–3.97). Conclusions: Compared with nonfrail patients, frail LT recipients had a higher risk of post-LT death and greater post-LT health care utilization, although overall post-LT survival was acceptable. These data lay the foundation to investigate whether targeting pre-LT frailty will improve post-LT outcomes and reduce resource utilization.
AB - Background and Aims: Frailty is a well-established risk factor for poor outcomes in patients with cirrhosis awaiting liver transplantation (LT), but whether it predicts outcomes among those who have undergone LT is unknown. Approach and Results: Adult LT recipients from 8 US centers (2012–2019) were included. Pre-LT frailty was assessed in the ambulatory setting using the Liver Frailty Index (LFI). “Frail” was defined by an optimal cut point of LFI ≥ 4.5. We used the 75th percentile to define “prolonged” post-LT length of stay (LOS; ≥12 days), intensive care unit (ICU) days (≥4 days), and inpatient days within 90 post-LT days (≥17 days). Of 1166 LT recipients, 21% were frail pre-LT. Cumulative incidence of death at 1 and 5 years was 6% and 16% for frail and 4% and 10% for nonfrail patients (overall log-rank p = 0.02). Pre-LT frailty was associated with an unadjusted 62% increased risk of post-LT mortality (95% CI, 1.08–2.44); after adjustment for body mass index, HCC, donor age, and donation after cardiac death status, the HR was 2.13 (95% CI, 1.39–3.26). Patients who were frail versus nonfrail experienced a higher adjusted odds of prolonged LT LOS (OR, 2.00; 95% CI, 1.47–2.73), ICU stay (OR, 1.56; 95% CI, 1.12–2.14), inpatient days within 90 post-LT days (OR, 1.72; 95% CI, 1.25–2.37), and nonhome discharge (OR, 2.50; 95% CI, 1.58–3.97). Conclusions: Compared with nonfrail patients, frail LT recipients had a higher risk of post-LT death and greater post-LT health care utilization, although overall post-LT survival was acceptable. These data lay the foundation to investigate whether targeting pre-LT frailty will improve post-LT outcomes and reduce resource utilization.
UR - http://www.scopus.com/inward/record.url?scp=85122101479&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122101479&partnerID=8YFLogxK
U2 - 10.1002/hep.32268
DO - 10.1002/hep.32268
M3 - Article
C2 - 34862808
AN - SCOPUS:85122101479
SN - 0270-9139
VL - 75
SP - 1471
EP - 1479
JO - Hepatology
JF - Hepatology
IS - 6
ER -